Literature DB >> 3108924

Differential effects of proglumide on mesolimbic and nigrostriatal dopamine function.

J G Csernansky, S Glick, J Mellentin.   

Abstract

Cholecystokinin octapeptide (CCK-8) is prevalent as a co-transmitter in the mesolimbic dopamine pathway. The effect of proglumide, a CCK-8 antagonist, on two acute and one chronic behavioral models of dopamine function was tested. First, haloperidol was used to inhibit stereotypies induced by apomorphine in rats. Pre-administration of proglumide significantly shifted the haloperidol dose response curve to the left. Second, rats were injected in the left caudate nucleus with kainic acid. Three weeks later, haloperidol was used to inhibit apomorphine-induced circling. Pre-administration of proglumide had no effect on this haloperidol dose response curve. Third, either proglumide, haloperidol, or combined treatment was administered to rats for 2 weeks. In proglumide-treated animals, a significant increase in 3H-spiperone binding sites in the nucleus accumbens was observed.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3108924     DOI: 10.1007/bf00216008

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  29 in total

1.  A potent nonpeptide cholecystokinin antagonist selective for peripheral tissues isolated from Aspergillus alliaceus.

Authors:  R S Chang; V J Lotti; R L Monaghan; J Birnbaum; E O Stapley; M A Goetz; G Albers-Schönberg; A A Patchett; J M Liesch; O D Hensens
Journal:  Science       Date:  1985-10-11       Impact factor: 47.728

2.  Peptide-monoamine coexistence: studies of the actions of cholecystokinin-like peptide on the electrical activity of midbrain dopamine neurons.

Authors:  L R Skirboll; A A Grace; D W Hommer; J Rehfeld; M Goldstein; T Hökfelt; B S Bunney
Journal:  Neuroscience       Date:  1981       Impact factor: 3.590

3.  Differential cataleptogenic and antistereotypic effects of caerulein and haloperidol.

Authors:  G Zetler
Journal:  Neuropharmacology       Date:  1981-07       Impact factor: 5.250

4.  Effects of cholecystokinin on apomorphine-induced changes of motility in rats.

Authors:  G Katsuura; S Itoh; J F Rehfeld
Journal:  Neuropharmacology       Date:  1984-07       Impact factor: 5.250

5.  Chronic proglumide increases [3H]spiperone binding in the rat brain.

Authors:  A J Bean; W J Baldy; G E Martin
Journal:  Eur J Pharmacol       Date:  1985-10-29       Impact factor: 4.432

6.  Antistereotypic effects of cholecystokinin octapeptide (CCK-8), ceruletide and related peptides on apomorphine-induced gnawing in sensitized mice.

Authors:  G Zetler
Journal:  Neuropharmacology       Date:  1985-03       Impact factor: 5.250

7.  CCK-8 modulation of mesolimbic dopamine: antagonism of amphetamine-stimulated behaviors.

Authors:  L H Schneider; J E Alpert; S D Iversen
Journal:  Peptides       Date:  1983 Sep-Oct       Impact factor: 3.750

8.  Proglumide fails to increase food intake after an ingested preload.

Authors:  L H Schneider; J Gibbs; G P Smith
Journal:  Peptides       Date:  1986 Jan-Feb       Impact factor: 3.750

9.  Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Correlation with psychosis and response to neuroleptic treatment.

Authors:  D Pickar; R Labarca; A R Doran; O M Wolkowitz; A Roy; A Breier; M Linnoila; S M Paul
Journal:  Arch Gen Psychiatry       Date:  1986-07

10.  Effects of cholecystokinin octapeptide on striatal dopamine metabolism and on apomorphine-induced stereotyped cage-climbing in mice.

Authors:  G L Kovács; G Szabó; B Penke; G Telegdy
Journal:  Eur J Pharmacol       Date:  1981-01-29       Impact factor: 4.432

View more
  1 in total

1.  Cholecystokinin and psychiatric disorders : role in aetiology and potential of receptor antagonists in therapy.

Authors:  J Shlik; E Vasar; J Bradwejn
Journal:  CNS Drugs       Date:  1997-08       Impact factor: 5.749

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.